For citations:
Fedorova AV, Banshchikova NE, Sizikov AE, Mullagaliev AA, Letyagina EA, Akimova AA, Ilyina NA, Kurochkina YD, Ubshaeva YB, Omelchenko VO, Chumasova OA, Shkaruba NS, Korolev MA. Results of a 24-week open-label, non-interventional study on the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2024;18(3):25-31. https://doi.org/10.14412/1996-7012-2024-3-25-31
Email this article 